Completed

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Chronic Disease+14

+ Hematologic Diseases

+ Immune System Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: April 2004
See protocol details

Summary

Principal SponsorSpectrum Pharmaceuticals, Inc
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2004

Actual date on which the first participant was enrolled.

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Official TitleA Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma 
NCT00090090
Principal SponsorSpectrum Pharmaceuticals, Inc
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

114 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseHematologic DiseasesImmune System DiseasesImmunoproliferative DisordersLeukemiaLeukemia, LymphoidLymphatic DiseasesLymphomaLymphoma, Non-HodgkinLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypePathologic ProcessesLeukemia, B-CellLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellDisease Attributes

Criteria

Inclusion Criteria: * Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma * at least one prior cytotoxic chemotherapy regimens * measurable disease * adequate bone marrow, liver and kidney function * ECOG PS 0-2 Exclusion Criteria: * prior treatment with elsamitrucin * prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment * HIV positive or known AIDS syndrome * uncontrolled medical disease or psychiatric condition/s

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 7 locations

Suspended

Alta Bates Cancer Center

Berkeley, United StatesSee the location
Suspended

Providence Saint Joseph Medical Center

Burbank, United States
Suspended

USC Norris Cancer Center

Los Angeles, United States
Suspended

Tower Hematology Oncology Medical Group

Los Angeles, United States
Completed7 Study Centers